Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 6/20 | 0.48 |
| ▸ | GCKR | Q14397 | 7/20 | 0.45 |
| ▸ | F13A1 | P00488 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5480564 | 1.00 | CXCR3 (0.48) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL6357386 | 1.00 | CXCR3 (0.48) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL6408554 | 0.92 | CXCR3 (0.48) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL5748862 | 0.91 | CXCR3 (0.46) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL5747872 | 0.91 | GCKR (0.45) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL27754624 | 0.91 | GCKR (0.45) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL5795980 | 0.90 | CXCR3 (0.48) | CXCR3GCKRF13A1TGM2TGM1 | |
| SCHEMBL6346422 | 0.89 | F13A1 (0.41) | CXCR3F13A1TGM2TGM1KDM4E | |
| SCHEMBL5748912 | 0.89 | F13A1 (0.41) | CXCR3F13A1TGM2TGM1KDM4E | |
| SCHEMBL6349119 | 0.88 | GCKR (0.43) | GCKRF13A1TGM2TGM1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | KALYPSYS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234046-A1 | Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders | PPARA, PPARG, PPARD | CXCR3 3739/4885GCKR 50/4885F13A1 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.